

Special Issue

Advancements in Cardiometabolic Pharmacology Research

Message from the Guest Editor

Cardiometabolic diseases, including hypertension, diabetes, and dyslipidemia, remain leading causes of morbidity and mortality worldwide, necessitating continuous advancements in pharmacological interventions. Over the years, research has evolved from conventional drug therapies to innovative approaches targeting molecular, genetic, and metabolic pathways. This Special Issue aims to highlight novel pharmacological strategies that address cardiometabolic dysfunctions, focusing on mechanisms, therapeutic targets, and translational applications. We seek to explore the interplay between pharmacology and pathophysiological processes, emphasizing drug discovery, bioactive compounds, and gut microbiome interactions in the treatment of these conditions. We invite cutting-edge research on the development and optimization of pharmacological agents, including natural and synthetic compounds with cardioprotective properties. Studies utilizing advanced experimental models, including preclinical in vivo and in vitro approaches, are particularly welcome. Research focusing on the efficacy, safety, and mechanistic insights of novel interventions will be prioritized.

Guest Editor

Dr. Gustavo Rodrigues Pedrino

Department of Physiological Science, Biological Sciences Institute,
Federal University of Goiás, Estrada do Campus, s/n, Goiânia 74690-
900, GO, Brazil

Deadline for manuscript submissions

30 September 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/236144

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)